Reduced immunogenic response to residual CHO cell protein in recombinant factor IX (IB1001) drug product in normal healthy rabbits

Haemophilia. 2016 May;22(3):e220-2. doi: 10.1111/hae.12890. Epub 2016 Feb 25.

Authors

P Cheung¹, A Emanuel¹, J Heward², J Maddalena³, D Toth¹, L Saward¹, S Kodihalli¹

Affiliations

¹ Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
² MPI Research, Mattawan, MI, USA.
³ HTI, Essex Junction, VT, USA.

PMID: 26915600
DOI: 10.1111/hae.12890

No abstract available

Publication types

Letter

MeSH terms

Animals
Antibodies / blood
CHO Cells
Complex Mixtures / immunology*
Complex Mixtures / therapeutic use
Cricetulus
Enzyme-Linked Immunosorbent Assay
Factor IX / immunology*
Factor IX / therapeutic use
Female
Hemophilia B / drug therapy*
Humans
Immunity, Humoral
Male
Protein Engineering
Rabbits
Recombinant Proteins / immunology*
Recombinant Proteins / therapeutic use

Substances

Antibodies
Complex Mixtures
IB1001
Recombinant Proteins
Factor IX